The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® ( RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...
Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.